RINVOQ 45 mg, extended-release tablet 28 tablets
Active ingredients: Upadacitinib, Upadacitinib hemihydrate
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RINVOQ 45 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC polyéthylène polychlortrifluoroéthylène aluminium avec calendrier de 28 comprimé(s)
- Marketing authorisation holder
- ABBVIE DEUTSCHLAND (ALLEMAGNE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 20 Feb 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66709721CIP73025473CIP133400930254738Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| UPADACITINIB HÉMIHYDRATÉcomprimé | — | SA |
| UPADACITINIBcomprimé | 45 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.